1/121
Looks like no tags are added yet.
tamoxifen
VTE, hot flashes endometrial cancer, cataracts
aromatase inhibitor
arthralgia, myalgia, bone loss, fracture risk, lipid effects
kadcyla (ado-trastuzumab)
thrombocytopenia, transaminitis, tbili elevation, neuropathy, cardiac monitoring
neratinib
breast
diarrhea → use ppx antidiarrheal
capecitabine
hand-foot syndrome, diarrhea, mucositis
take with food
olaparib
breast, prostate, ovarian(BRCA-mutated (usually HRD+); BRCA wild-type, HRD+ WITH BEV); BRCA1/2
anemia, neutropenia, fatigue, nausea, rare MDS/AML, pneumonitis, scr increase; CYP3A4 substrate
alpelisib
PIK3CA, breast
hyperglycemia, rash diarrhea. frequent and early glucose monitoring. can consider ppx nonsedating antihistamine
inavolisib
PIK3CA, breast
hyperglycemia, diarrhea, stomatitis, neutropenia
elacestrant
ESR1, breast
nausea, fatgue, arthtralgia
capivaserib
PTEN, breast
rash, diarrhea
everolimus
stomatitis → can use dex mouthwash
pneumonitis
trastuzumab dexrutecan (enhertu)
ILD/pneumonitis, nausea, myelosuppression
datopotamab dexrucan
breast
severe neutropenia, diarrhea
palbociclib
breast, CDK4/6
neutropenia, CBC monitoring
ribociclib
breast, CDK4/6
neutropenia, QT prolongation, hepatotoxicity, ECG, electrolytes, CBC, LFT monitoring
abemaciclib
breast, CDK4/6
diarrhea, less neutropenia that other CDK4/6 I, VTE, hepatotoxicity
AML defining cytogenesis
t(8;21), inv(16/t(16;16), t(15;17)
Ph+ALL
philadelphia positive; t(9;22)/BCR::ABL1. Hyper-CVAD+imatinib/dasatinib/ponatinib
asparginase
pancreatis, thrombosis, intracranial hemorrhage, hypofigrinogenemia, TG increase, hyperglycemia, hepatotoxicity
blina
CRS, ICANS; CD19
inotuzumab
VOS/SOS; CD22
gemtuzumab
VOD/SOS, hepatotoxicity, infusion reactions, myelosuppression
FLT3 inhibitors
QTc and CYP interactions; quizartinib → major QT considerations
IDH/menin inhibitors
differential syndrome: fever, edema/wt gain, pulmonary infiltrates/hypoxia, hypotension, renal dysfunction
PML::RARA t (15;17)
APL
del(5q)
use lenalidomide in MDS
BTK inhibitor
CLL
class SE: afib, bleeding, hypertension, infection
ibrutinib: diarrhea, arthralgia, drug interaction. Most risk for afib. not preferred due to toxicity
acalabrutinib: HA, cytopenia. less afib than ibrutinib
zanubrutinib: neutropenia. more neutropenia but better PFS and safety outcomes compared to ibrutnib
pirtobrutinib: bibcivalent. infection, bleeding, neutropenia
venetoclax
CLL
TLS, neutropenia, infection, CYP3A/P-gp interactions
Mosunetuzumab
Follicular lymphoma after 2 lines; CD20xCD3 T cell engager
Step up dosing
Bbw: CRS, neurological toxicity, fatigue, rash, pyrexia, cytopenia
obinutuzumab
CLL
infusion reaction, neutropenia, infection, HBV reactivation risk
PI3K inhibitor
immune-mediated colitis, hepatotoxicity, pneumonitis, infection, opportunistic infection concerns
imatinib
CML, ALL. first gen
SE: edema, muscle cramps, nausea, diarrhea, rash myelosuppression, hepatotoxicity
not preferred for intermediate/high risk CML
dasatinib
CML, ALL. second gen
SE: pleural effusion, pulmonary arterial hypertension, plt dysfunction/bleeding, myelosuppression
avoid taking with PPI
crosses blood brain barrier
nilotinib
CML. second gen
arterial occlusive events, hyperglycemia, hyperlipidemia, pancreatitis, QT prolongation
administer fasting. metabolic/cardiovascular monitoring
CML F317L
bosutinib
CML, ALL. second gen
diarrhea, nausea, hepatotoxicity, myelosuppression, renal function changed
CML F317L
ponatinib
CML. second gen
,hypertension, pancreatitis, hepatotoxicity, thrombosis
reserves for resistant disease/T315I with risk-adapted dosing. CML F317L
asciminib
CML, T315I
myelosuppression, hypertension, pancreatic enzyme elevation/pancreatitis, cardiovascular toxicity,
apalutamide
prostate
rash, fracture/falls, fatigue, hypothyroidism, HTN, seizure
strong CYP induction
darolutamide
prostate
lower CNS penetration → fewer CNS effects/DDIs
600mg bid with food
enzalutamide
prostate
fatigue, falls/fracture, HTN, seizure
strong CYP3A4 induction
abiraterone
prostate (only for mets CSPC)
always give with prednisone
mineralocorcicoid excess: HTN, hypokalemia, edema
hepatotoxicity
CYP3a4 substrate
mitoxanthrone
prostate
myelosuppression, cardiotoxicity
cabazitaxel
prostate
severe neutropenia, FN, diarrhea, neuropathy
lupron, goserelin, triptorelin
gnRH/LHRH agonist; ADT
erdafitinib
bladder, billiary tract FGFR1,2,3,4
hyperphosphatemia, ocular toxicity
lenvatinib
renal, liver, endometrial; VEGFR TKI “similar to bev”
hypertension, hypothyroidism, diarrhea, fatigue, proteinuria, rash, immune AE, HFS
axitinib
renal; VEGFR TKI
hypertension, transaminitis, HFS, immune AE
metabolized by CYP3A4
cabozatinib
renal; VEGFR TKI
shows intracranial response
diarrhea, hypothyroidism, transaminitis, rash, hypertension, HFS
cetuximab/panitumumab
colon; EGFR
rash, hypomagnesemia
Lu-177 PSMA-617
prostate
PSMA-positive mCRPC.
sorafenib
liver
HFS, diarrhea, rash, hypertension, fatigue; reduce start dose for hepatic/renal dysfunction
FGFR
cholangio
futibatinib, pemigatinibm erdafitinib
SE: hyperphophatemia, derm (HFS, alopecia, pronychia, dry skin, xerotomia, stomatitis
ocular toxicity
pralsetinib
RET; cholangio
KRAS or NRAS mutation in CRC
lacks benefit from cetuximab or panitumumab
HER2 in CRC
resistance to EGFR antibodies
BRCA½ or PALB2 in pancreas
favor platinum
selpercatinib
RET; pancreas
HRD+ in ovarian
platinum and PARPi sensitivity
niraparib
ovarian, BRCA wild-type, HRD+; BRCA-mutated (usually HRD+); maintenance; PARPi
thrombocytopenia, neutropenia, mds/aml, HTN, palpitation
200mg qd is wt <77kg or BL plt<150k; otherwise 300mg
tisotumab
tissue factor directed ADT; recurrent/met cervical Ca
ocular toxicity, bleeding, neuropathy
slim crab
MM
crab: at least 1qualifying
c: hypercalcemia; corrected calcium>11.5
r: renal; scr>2, crcl<40N
a: anemia; hgb<10 or 2< less than lln
b: bone lesion
s: bone marrow plasma cell>60
li: involved:uninvolved light chain ratio >100
mri: more than 1 focal lesion
MM high risk
del (17p)/tp53, t(4;14), t(14;16), t(14;20), gain/amp 1q and del(1p)
high beta-2 microglobulin with normal renal function, high plasma-cell s phase, plasma cell leukemia, extramedullary disease
erlotinib
pancreas
SE: rash
pralsetinib
RET; cholangiocarcinoma
BRAFV600E in CRC
encorafenib+antiEGFR+chemo
BRAFV600E in pancreas
dabrafenib/trametinib
pemigatinib
FGFR inhibitor
cholangiocarcinoma
regorafenib
CRC
dosing: 80mg→120mg→160mg
SE: HFS, hypertension, hepatotoxicity
zolbetuximab
gastric cancer/CLDN18.2
SE: N/V; PDL-1>1%
agnotistic - MSI-H/dMMR; TMB-H>10
pembro
agnotistic dMMR
dostarlimab
agnotistic - NTRK fusion
larotrectinib, entrectinib, repotrectenib
agnotistic - BRAFV600E
dabrafenib+trametinib (CRC EXCEPTION - ecorafenib+cetuximab)
agnotistic - RET fusion
selpercatinib (CAT RAT)
HER2 IHC 3+
enhertu
lonsurf
CRC, GEJ
severe neutropenia
rucaparib
ovarian BRCA wild-type, HRD+; BRCA-mutated (usually HRD+); PARPi
AST/ALT, cholesterol and SCr elevation, CYP interaction
PARPi class SE
anemia, thrombocytopenia/neutropenia, fatigue, nausea, GI, rare MDS/AML
mirvetuximab
overian; Fralpha
6mg/kg adjusted bw q21d
ocular, neuropathy, Gi toxicity, cytopenia
tacrolimus
GVHD ppx
nephrotoxicity, creatinine, hepatice, electrolyte. can increase blood pressure
CYP3A4
target level 5-20
Letermovir+tacrolimus
letemovir=CMV ppx
Letermovir inhibits CYP3A4, increase tacrolimus concentration
Azole/Aprepitant/letermovir+tacrolimus/cyclosporine/sirolimus/rutolitinib
Aprepitant/azole/letermovir CYP3a4 inhibitor. Increaes other drugs concentration
busulfan
HSCT conditioning
SE: seizures (ppx: keppra, ativan), SOS/VOD
AUc dosing, high emetogenic, avoid tylenol
cyclophosphamide
hemorrhagic cystitis, cardiotoxicity
mycophenolate
gvhd
gi toxicity
ruxolitinib
chronic/acute gvhd tx, ppx
cytopenia, infection
defibrotide
severe sos/vod
bleeding
ursodiol
sos/vod ppx
belumosudil
chronic gvhd tx
rock2 (beluga’s head looks like a rock)
axatinib
chronic gvhd tx
csf-1r
acute gvhd what organs?
skin, liver, gi
BRCA1/2 cancers
breast, ovarian, prostate, pancrease
Lynch syndrome cancers
CRC, small bowel, gastric, endometrial, ovarian, pancreas, biliary, urolithial
Li Fraumeni syndrome cancer
TP53
soft tissue sarcoma, osteosarcoma, breast, leukemia, brain, adernocortical carcinoma
osimertinib
lung; EGFR TKI
CNS penetration and activity against EGFR exon 19 deletion, L858R, and T790M
QT prolongation, cardiomyopathy, and interstitial lung disease.
alectinib
lung; ALK inhibitor
good CNS activity
CPK elevation, hepatotoxicity, bradycardia
brigatinib
lung; ALK inhibitor
Early pulmonary events, hypertension, CPK elevation